Myocarditis following the use of different immune checkpoint inhibitor regimens: A real-world analysis of post-marketing surveillance data.

CONCLUSIONS: Analysis of FAERS data provides more precise profile on the occurrences and characteristics of myocarditis after different ICI regimens. The findings support continued surveillance, risk factor identification, and comparative studies. PMID: 31491729 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31491729?dopt=Abstract

Source: International Immunopharmacology - September 2, 2019 Category: Allergy & Immunology Authors: Fan Q, Hu Y, Yang C, Zhao B Tags: Int Immunopharmacol Source Type: research

More News: Allergy & Immunology | Myocarditis | Study | Yervoy